Connection

Richard Klein to Diabetes Mellitus, Type 1

Back to Details
This is a "connection" page, showing publications Richard Klein has written about Diabetes Mellitus, Type 1.
Richard Klein
Connection Strength
2.810
Diabetes Mellitus, Type 1
  1. Decreased plasma levels of select very long chain ceramide species are associated with the development of nephropathy in type 1 diabetes. Metabolism. 2014 Oct; 63(10):1287-95.
    View in: PubMed
    Score: 0.328
  2. LDL-containing immune complexes in the DCCT/EDIC cohort: associations with lipoprotein subclasses. J Diabetes Complications. 2011 Mar-Apr; 25(2):73-82.
    View in: PubMed
    Score: 0.247
  3. Apolipoprotein C-III protein concentrations and gene polymorphisms in Type 1 diabetes: associations with microvascular disease complications in the DCCT/EDIC cohort. J Diabetes Complications. 2005 Jan-Feb; 19(1):18-25.
    View in: PubMed
    Score: 0.170
  4. Apolipoprotein C-III protein concentrations and gene polymorphisms in type 1 diabetes: associations with lipoprotein subclasses. Metabolism. 2004 Oct; 53(10):1296-304.
    View in: PubMed
    Score: 0.167
  5. In vivo glycated low-density lipoprotein is not more susceptible to oxidation than nonglycated low-density lipoprotein in type 1 diabetes. Metabolism. 2004 Aug; 53(8):969-76.
    View in: PubMed
    Score: 0.165
  6. Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort. Diabetes Care. 2003 May; 26(5):1439-48.
    View in: PubMed
    Score: 0.151
  7. Plasma apoM Levels and Progression to Kidney Dysfunction in Patients With Type 1 Diabetes. Diabetes. 2022 08 01; 71(8):1795-1799.
    View in: PubMed
    Score: 0.143
  8. Serum apolipoproteins and apolipoprotein-defined lipoprotein subclasses: a hypothesis-generating prospective study of cardiovascular events in T1D. J Lipid Res. 2019 08; 60(8):1432-1439.
    View in: PubMed
    Score: 0.115
  9. Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes. J Clin Lipidol. 2019 May - Jun; 13(3):481-491.e1.
    View in: PubMed
    Score: 0.114
  10. Apolipoprotein-defined lipoprotein subclasses, serum apolipoproteins, and carotid intima-media thickness in T1D. J Lipid Res. 2018 05; 59(5):872-883.
    View in: PubMed
    Score: 0.106
  11. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.
    View in: PubMed
    Score: 0.103
  12. Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study. Neuromolecular Med. 2017 Mar; 19(1):46-56.
    View in: PubMed
    Score: 0.094
  13. Associations between intensive diabetes therapy and NMR-determined lipoprotein subclass profiles in type 1 diabetes. J Lipid Res. 2016 Feb; 57(2):310-7.
    View in: PubMed
    Score: 0.090
  14. Plasma Prekallikrein Is Associated With Carotid Intima-Media Thickness in Type 1 Diabetes. Diabetes. 2016 Feb; 65(2):498-502.
    View in: PubMed
    Score: 0.090
  15. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016 Jan; 244:93-100.
    View in: PubMed
    Score: 0.090
  16. Longitudinal Association Between Endothelial Dysfunction, Inflammation, and Clotting Biomarkers With Subclinical Atherosclerosis in Type 1 Diabetes: An Evaluation of the DCCT/EDIC Cohort. Diabetes Care. 2015 Jul; 38(7):1281-9.
    View in: PubMed
    Score: 0.086
  17. Plasma total homocysteine and carotid intima-media thickness in type 1 diabetes: a prospective study. Atherosclerosis. 2014 Sep; 236(1):188-195.
    View in: PubMed
    Score: 0.082
  18. Response to comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e108-9.
    View in: PubMed
    Score: 0.080
  19. Apolipoprotein-defined lipoproteins and apolipoproteins: associations with abnormal albuminuria in type 1 diabetes in the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort. J Diabetes Complications. 2013 Sep-Oct; 27(5):447-53.
    View in: PubMed
    Score: 0.077
  20. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes Care. 2013 Aug; 36(8):2317-23.
    View in: PubMed
    Score: 0.075
  21. Cross-sectional associations of C-reactive protein with vascular risk factors and vascular complications in the DCCT/EDIC cohort. J Diabetes Complications. 2008 May-Jun; 22(3):153-63.
    View in: PubMed
    Score: 0.053
  22. Increased methionine sulfoxide content of apoA-I in type 1 diabetes. J Lipid Res. 2008 Apr; 49(4):847-55.
    View in: PubMed
    Score: 0.052
  23. 'Lipoproteins, glycoxidation and diabetic angiopathy'. Diabetes Metab Res Rev. 2004 Sep-Oct; 20(5):349-68.
    View in: PubMed
    Score: 0.041
  24. Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci. 2004 Mar; 45(3):910-8.
    View in: PubMed
    Score: 0.040
  25. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar; 26(3):810-8.
    View in: PubMed
    Score: 0.037
  26. Risk factors related to inflammation and endothelial dysfunction in the DCCT/EDIC cohort and their relationship with nephropathy and macrovascular complications. Diabetes Care. 2008 Oct; 31(10):2006-12.
    View in: PubMed
    Score: 0.014
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.